S
0.029
0.01 (22.46%)
Previous Close | 0.024 |
Open | 0.025 |
Volume | 91,438 |
Avg. Volume (3M) | 22,361,615 |
Market Cap | 775,459 |
Price / Sales | 2.27 |
Price / Book | 10.65 |
52 Weeks Range | |
Earnings Date | 25 Apr 2025 - 28 Apr 2025 |
Operating Margin (TTM) | -28,891.71% |
Diluted EPS (TTM) | -3.07 |
Current Ratio (MRQ) | 2.25 |
Operating Cash Flow (TTM) | -100.02 M |
Levered Free Cash Flow (TTM) | -57.94 M |
Return on Assets (TTM) | -59.88% |
Return on Equity (TTM) | -776.96% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Syros Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
-1.3
Analyst Consensus | NA |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -2.0 |
Average | -1.33 |
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 0.76% |
% Held by Institutions | 33.96% |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
28 Feb 2025 | Announcement | Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |